|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Pfizer |
| Information provided by: | Pfizer |
| ClinicalTrials.gov Identifier: | NCT00601484 |
Purpose
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
| Condition | Intervention | Phase |
|
Cystitis, Interstitial Painful Bladder Syndrome |
Drug: PF-04383119 Drug: Placebo |
Phase II |
| MedlinePlus related topics: | Interstitial Cystitis |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of PF-04383119 for the Treatment of Pain Associated With Interstitial Cystitis |
| Estimated Enrollment: | 64 |
| Study Start Date: | March 2008 |
| Estimated Study Completion Date: | December 2008 |
| Arms | Assigned Interventions |
| 2: Placebo Comparator |
Drug: Placebo
placebo IV, single dose
|
| 1: Experimental |
Drug: PF-04383119
PF-04383119 200 mcg/kg IV, single dose
|
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Pfizer CT.gov Call Center | 1-800-718-1021 |
| United States, Arizona | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Peoria, Arizona, United States, 85381 | |||||
| United States, California | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Fresno, California, United States, 93710 | |||||
| United States, Colorado | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Boulder, Colorado, United States, 80304 | |||||
| United States, Connecticut | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Hartford, Connecticut, United States, 06041 | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Hartford, Connecticut, United States, 06106 | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Middlebury, Connecticut, United States, 06762 | |||||
| United States, Georgia | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Atlanta, Georgia, United States, 30308 | |||||
| United States, Indiana | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Jeffersonville, Indiana, United States, 47130 | |||||
| United States, Louisiana | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Shreveport, Louisiana, United States, 71106 | |||||
| United States, Maryland | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Owings Mills, Maryland, United States, 21117 | |||||
| United States, Michigan | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Royal Oak, Michigan, United States, 48073 | |||||
| United States, Nebraska | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Omaha, Nebraska, United States, 68114 | |||||
| United States, North Carolina | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Greensboro, North Carolina, United States, 27403 | |||||
| United States, Ohio | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Cincinnati, Ohio, United States, 45212 | |||||
| United States, Pennsylvania | |||||
| Pfizer Investigational Site | Not yet recruiting | ||||
| Pittsburgh, Pennsylvania, United States, 15212 | |||||
| United States, South Carolina | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Greer, South Carolina, United States, 29650 | |||||
| United States, Texas | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Houston, Texas, United States, 77024 | |||||
| United States, Washington | |||||
| Pfizer Investigational Site | Recruiting | ||||
| Spokane, Washington, United States, 99207 | |||||
| Pfizer |
| Study Director: | Pfizer CT.gov Call Center | Pfizer |
More Information
To obtain contact information for a study center near you, click here. 
  |
| Responsible Party: | Pfizer, Inc. ( Director, Clinical Trials Disclosure Group ) |
| Study ID Numbers: | A4091010 |
| First Received: | January 15, 2008 |
| Last Updated: | April 22, 2008 |
| ClinicalTrials.gov Identifier: | NCT00601484 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|